Products
Colon cancer genetic testing
Colorectal cancer is one of the major cancers that seriously threatens the life and health of Chinese residents, causing a serious social burden. In 2020, there were about 555,000 new cases of CRC in my country, accounting for 12.2% of the number of new cancers in my country that year; 83% of CRC patients are in the middle and late stages at the time of diagnosis and miss the opportunity for surgical treatment.
OncoCruise 11 Genes - the optimal solution for clinical decision-making of colorectal cancer precision diagnosis and treatment
Technical advantages
Using advanced next-generation sequencing technology to sequence the point mutations, amplifications, fusions, rearrangements, insertions, deletions and other variants of 11 druggable target genes with clinical evidence for lung cancer, for clinical treatment decision-making and targeting Treatment provides sound and reliable advice.
Beneficial population
1. Colorectal cancer patients who need targeted therapy
2. Patients requiring postoperative adjuvant therapy for colorectal cancer
Clinical significance
1. Help to choose the correct targeted drugs, avoid ineffective treatment, and improve the quality of life
2. Simultaneously analyze sensitive mutations and drug-resistant mutations, prompting the medication information of more than 40 targeted drugs
Test content
Sampling Guidelines
Tissue Sample
Blood Sample